Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


At the present time ischemic heart disease (IHD) continues to be the leading cause of cardiovascular mortality. Improvement of treatment methods is an important aspect in reduction of IHD fatal complications.
Aim. To carry out a meta-analysis of several clinical and epidemiological studies with research on the use of drugs with established prognostic effect in patients with IHD.
Material and methods. Analysis of dynamics in drug prescription in IHD was conducted based on Russian clinical and epidemiological trials, performed from 2004 to 2009 years.
Results. The total amount of patients was 17345. Majority of them suffered from arterial hypertension (81.6%), one third had a history of myocardial infarction, more than a half revealed heart failure (59.8%). At that history of diabetes mellitus was only registered in 10.5% of the patients varying from 8% to 17.6%. Lipid metabolism disorders were present in more than a half of the patients. On the average one in four patients was obese.
At drug therapy analysis it was found out that 6.4% of the IHD patients received no medications. Statins intake increased from 5.3% to 85.7% in men and from 9.6% to 69.3% in women in last 5 years. Incidence of the renin-angiotensin-aldosterone system blockers intake increased by 13% in the both genders. Men with IHD received antiplatelet agents more often than women. So, only 45.9% of women received these drugs in 2004 and 57.9% in 2009, while men increased antiplatelet agents use from 58.5% in 2004 to 63.5% in 2009. Men received beta-block- ers by 14% more often in 2009 (74.6%) than in 2004 and women – by 30% (82.4%).
Conclusion. The incidence of the prescription of the drugs with established prognostic value has increased recently. At that rate of IHD mortality in cardiovascular mortality structure continues to be high probably due to inadequate treatment. First, the number of coronary surgical interventions in our patients is significantly lower than in the other countries. Second, despite con- siderable increase in the drug use, doses and adherence to treatment remain insufficient. Representative trials with participation of different-level healthcare institutions are reasonable.

About the Authors

S. A. Shalnova
State Research Center for Preventive Medicine, Moscow
Russian Federation
PhD, MD, Professor, Head of Department of Non-infectious Diseases Epidemiology, State Research Center for Preventive Medicine (SRCPM)

A. D. Deev
State Research Center for Preventive Medicine, Moscow
Russian Federation
PhD, Head of Laboratory of Biostatistics, SRCPM

S. A. Boytsov
State Research Center for Preventive Medicine, Moscow
Russian Federation
PhD, MD, Professor, Director of the SR- CPM, Head of Department of Clinical Cardiology and Molecular Genetics of the SRCPM


1. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death From 1950 to 1999. The Framingham Heart Study. Circulation 2004;110:522-7.

2. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011;32:5-22.

3. Laatikainen T, Critchley J, Vartiainen E, et al. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005;162:764-73.

4. Health and demographic indices of Russian Federation in 2011. Statistical handbook. Moscow: Russian Ministry of Health; 2013. Russian (Медико-демографические показатели Российской Федерации в 2011 году. Статистический справочник. М.: Минздрав России; 2013).

5. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association. Circulation 2011; 123:933- 44.

6. Overall morbidity in the adult population in Russia in 2011. Statistical materials, parts III, IV. Moscow: Rosstat; 2012. Russian (Общая заболеваемость взрослого населения России в 2011 году. Статистические материалы, части III, IV. М.: Росстат; 2012)

7. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380-6

8. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005;331:614.

9. Aspelund T, Gudnason V, Magnusdottir BT, et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One 2010;5(11):e13957.

10. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010;100(4):684-92.

11. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011;32:5-22.

12. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949-3003.

13. Chazov E.I., Oganov R.G., Poghosova N.V., et al. Depression in patients with arterial hypertension and coronary heart disease. The KOORDINATA clinical – epidemiological program: first results of multicenter study. Kardiologiia 2005; (11): 4-10. Russian (Чазов Е.И., Оганов Р.Г., Погосова Н.В., и др. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): первые результаты многоцентрового исследования. Кардиология 2005; (11): 4-10).

14. Shalnova SA, Deev AD. Characteristics of high-risk patients. The results of the epidemiological research and educational programs OSKAR. Cardiovascular Therapy and Prevention 2006; 6: 58-63. Russian (Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваскулярная Терапия и Профилактика 2006; (6): 58-63).

15. Shalnova SA, Deev AD, Karpov YA. Hypertension and coronary heart disease in the actual practice of a cardiologist. Cardiovascular Therapy and Prevention 2006; 1: 73-80. Russian (Шальнова С.А., Деев А.Д, Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача-кардиолога. Кардиоваскулярная Терапия и Профилактика 2006;(1): 73-80).

16. Bubnova MG, Aronov DM, Oganov RG, et al (on behalf of the researchers). Clinical characteristics and common approaches to the treatment of patients with stable angina in actual practice. Russian study PERSPEKTIVA (Part I). Cardiovascular Therapy and Prevention 2010; 9 (6): 47-56. Russian (Бубнова М.Г., Аронов Д.М., Оганов Р.Г., и др. (от имени исследователей). Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование ПЕРСПЕКТИВА (часть I). Кардиоваскулярная Терапия и Профилактика 2010; 9(6): 47-56).

17. Vasyuk YA, Shalnova SA, Shkolnik EL, Kulikov KG. The PRIMA study: trimetazidine modified release of the active ingredient in the treatment of patients with stable angina pectoris, myocardial infarc- tion. Epidemiological and clinical stages. Kardiologiia 2008; 48 (12): 10-3. Russian (Васюк Ю.А., Шальнова С.А., Школьник Е.Л., Куликов К.Г. Исследование ПРИМА: триметазидин с модифицированным высвобождением действующего вещества в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокарда. Эпидемиологический и клинический этапы. Кар- диология 2008; 48(12):10-3).

18. Shalnova SA, Oganov RG, Stag FG, Ford I. on behalf of the register CLARIFY Coronary Heart Disease. Modern reality according to the World Register CLARIFY. Kardiologiia 2013; 53 (8): 28-33. Russian (Шальнова С.А., Оганов Р.Г., Стэг Ф.Г., Форд И. от имени участников регистра CLARIFY Ишемическая болезнь сердца. Современная реальность по данным всемирного регистра CLARIFY. Кардиология 2013; 53(8): 28-33).

19. Kotseva K, Wood D, De Backer G, De Basquerb D, Pyorala K, Keild U, EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16:121-37.

20. Karpov YA, Deev AD (on behalf of program participants). The ALTERNATIVA Program Research antianginal effectiveness and tolerability of Procoralan (ivabradine) and evaluation of the quality of life patients with stable angina: results of epidemiological stages. Kardiologiia 2008; (5): 30-35. Russian (Карпов Ю.А., Деев А.Д. (от имени участников программы). Программа АЛЬТЕРНАТИВА — исследование АнтиангинаЛЬной эффекТивности и пЕРеносимости кораксаНА (ивабрадина) и оценка качесТва жИзни пациентоВ со стАбильной стенокардией: результаты эпидемиологического этапа. Кардиология 2008; 5: 30-5).

21. Tolpygina SN, Polyanskaya YN, Martsevich SYu. Treatment of patients with chronic coronary heart disease in real clinical practice according to the “IHD PROGNOSIS” registry data (Part 1). Rational Pharmacother Card 2013; 9 (2): 138-42. Russian (Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ишемической болезнью сердца в реальной клинической практике по данным регистра «ПРОГНОЗ ИБС» (часть 1). Рациональная Фармакотерапия в Кардиологии 2013; 9(2): 138-42).


For citation:

Shalnova S.A., Deev A.D., Boytsov S.A. DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2013;9(6):611-618.

Views: 678

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)